Periodic monitoring Active

Key facts

  • In December 2025, 11 EU/EEA countries reported 97 measles cases. Seventeen countries reported zero cases.
  • During the last 12-month period, eight deaths attributable to measles were reported to ECDC by France (4), Romania (3) and the Netherlands (1).
  • Overall, case numbers decreased compared with the previous months, which is consistent with the seasonality of measles.
  • Complementary epidemic intelligence surveillance was performed on 12 and 13 February 2026. Two outbreaks have been detected in France and Spain. Sporadic cases and clusters were reported in several EU/EEA countries. Updates are provided for some countries outside the EU/EEA.

Overview

Since March 2025, there has been an overall decrease in reported measles cases. As expected, the number of cases declined over the summer months, in line with the known seasonality of the disease.

In December 2025, 28 EU/EEA countries reported measles data, with 11 countries reporting 97 cases. Seventeen countries reported zero cases.

Overall, case numbers decreased compared with the previous month; however, this is subject to change in the event of a future retrospective update. The highest case counts were reported by Poland (27), Italy (25), Romania (12), France (10) and Spain (6).

Between 1 January 2025 and 31 December 2025, 30 EU/EEA countries reported a total of 7 655 measles cases, 5 762 (75.3%) of which were laboratory confirmed.

Of the 7 655 cases with known age, 3 072 (40.1%) were in children under five years old; 2 674 (34.9%) cases were in individuals 15 years old or above. The highest notification rates were observed among infants under one year old (261.6 cases per million population) and children one to four years old (127.4 cases per million population).

Of 7 210 cases (94.2% of all cases) with known age and vaccination status, 5 764 (79.9%) were unvaccinated, 743 (10.3%) were vaccinated with one dose of a measles-containing vaccine, 571 (7.9%) were vaccinated with two or more doses, and 122 (1.7%) were vaccinated with an unknown number of doses.

During the 12-month period, eight deaths (case fatality rate (CFR): 0.105%) attributable to measles were reported to ECDC by France (4), Romania (3) and the Netherlands (1). Detailed data are available in ECDC's Surveillance Atlas of Infectious Diseases.

Complementary epidemic intelligence surveillance was performed on 12 and 13 February 2026. Two outbreaks have been detected in France and Spain. Sporadic cases and clusters were reported in several EU/EEA countries. Outside the EU/EEA, updates have been provided for England, Israel, Ukraine, Africa CDC and the World Health Organization Pan American Health Organization (WHO PAHO) regions.

In January 2026, WHO announced that six countries in the World Health Organization’s European region, including the United Kingdom and Spain, have re-established endemic measles transmission based on reporting from 2024.

Disclaimer: The monthly measles report published in the CDTR provides the most recent data on cases and outbreaks based on information made publicly available by the national public health authorities or the media. Sometimes this information is made available retrospectively. This report is a supplement to ECDC’s monthly measles and rubella monitoring report, based on data routinely submitted by 30 EU/EEA countries to EpiPulse Cases. Data presented in the two monthly reports may differ.

Epidemiological summary for EU/EEA countries with relevant epidemic intelligence updates:

Bulgaria reported one new case in 2026 in week 7. In 2025, Bulgaria reported two cases.

Czechia reported three cases in 2026, as of 2 February.

France reported 12 cases and no deaths in January 2026. The cases were related to three clusters and are detected among adults and children.

An ongoing outbreak is reported in Val Thorens ski resort in Auvergne-Rhône-Alpes, involving four young adults. Cases were reported between 12 January and 4 February 2026. Two of the cases were not vaccinated, one was vaccinated and one had an unknown vaccination status. One of the four individuals was hospitalised.

Ireland reported three cases in weeks 4 and 5 in 2026. Data from Ireland (National Notifiable Disease Hub) includes confirmed, probable, and possible measles cases.

Italy reported 529 cases of measles (497 laboratory confirmed, 11 probable and 21 possible cases) from 1 January to 31 December 2025, an increase by 44 cases since 30 November 2025. Of the reported cases, 53 were in healthcare workers. Genotype D8 and B3 were detected in 144 and 145 samples, respectively.

The Netherlands reported one measles case in 2026 and as of 7 February. There is currently no indication of a national outbreak. In 2025, a total of 539 measles cases were reported to the National Institute for Public Health and the Environment (RIVM), of which 62 were contracted abroad.

Poland reported two cases of measles in January 2026.

Spain reported 32 cases of measles from 1 January to 8 February 2026, including three imported cases and two cases related to imported cases.

On 6 February 2026, according to a media report, the General Directorate of Public Health (DGSP) reported a workplace-associated measles outbreak involving employees of two companies located in the same building in the city of Alicante, Spain. Among 28 suspected cases, 16 have been laboratory confirmed, while nine remain under investigation. Public health authorities have implemented control measures, including isolation of confirmed and suspected cases and vaccination of identified contacts, to limit further transmission.

Sweden reported two cases in 2026, as of 13 February.

Epidemiological summary for EU/EEA outermost territories with relevant epidemic intelligence updates:

No new outbreaks or cases have been detected in the reporting period.

Epidemiological summary for select countries outside of the EU/EEA with relevant epidemic intelligence updates:

England reported 96 laboratory-confirmed cases since the start of 2026. Cases have increased in January, mostly driven by the ongoing outbreak in North London. The majority of cases involve children under 10 years old (77%).

Israel reported 988 measles hospitalisations since 2025 and as of 13 February 2026, including 14 deaths from measles.

Ukraine reported 1 502 measles cases from January to December 2025, an increase of 46 cases since November 2025.

According to a report by Africa CDC published on 28 January 2026, Mozambique and Liberia experienced measles outbreaks with moderate risk.

According to WHO PAHO, in 2026 (week 1–3), 1 031 measles cases and no deaths were reported in the Americas Region. Cases were notified by Mexico (740), the United States (US) (171), Canada (67), Bolivia (10), Guatemala (41), Chile (1) and Uruguay (1). This represents a 45‑fold increase compared with the same period in 2025 (23 cases). In 2025, the Region reported 14 891 confirmed cases and 29 deaths, 73% of which occurred in Indigenous populations. This represents a 32‑fold increase compared with 2024 (466 cases) and the highest annual total since 2019. Countries with the highest number of cases in 2025: Mexico (6 428 cases, 24 deaths), Canada (5 436 cases, two deaths), and the US (2 242 cases, three deaths)

For more information on the provisional number of cases outside the EU/EEA region, please visit the World Health Organization (WHO) website.

The numbers provided to WHO for EU/EEA countries are from EpiPulse Cases data, which are updated monthly and available on the ECDC Surveillance Atlas of Infectious Diseases. Due to differences in reporting times, the numbers may not correspond to the data from epidemic intelligence screening.

ECDC assessment

Although most recent cases were acquired through local or community transmission, travel-related cases continue to be reported.

Continued vigilance is essential due to sub-optimal vaccination coverage for measles-containing vaccines (MCV) in several EU/EEA countries, possible introduction from areas with ongoing transmission, and increased travel and population movement during holiday periods.

Actions

ECDC is monitoring the measles situation through its epidemic intelligence activities. Data collected via epidemic intelligence supplement the monthly outputs of measles surveillance data from EpiPulse Cases, which are routinely submitted by 30 EU/EEA countries.

ECDC urges EU/EEA public health authorities to focus on the following areas:

  • Close immunity gaps, achieve and maintain high vaccination coverage for measles-containing vaccines (>95% with the second dose). It is vital to ensure first and second dose vaccinations are administered on time, as per national schedules among infants and children. It is also important to identify and vaccinate eligible individuals (for example, non-immune adolescents and adults) in immunisation catch-up programmes (as recommended by local and national authorities).
  • Strive towards high-quality surveillance and adequate public health capacity, especially for early detection, diagnosis, response and control of outbreaks.
  • Increase the clinical awareness of health professionals, including reminding them of the importance of checking individuals' vaccination status ahead of travel.
  • Healthcare professionals should be fully vaccinated.
  • Promote vaccine acceptance and uptake by employing specific risk communication strategies and identifying drivers of suboptimal MMR vaccine acceptance and uptake to ensure that tailored interventions are implemented in response.
  • Address barriers and engage with populations underserved by healthcare services. Systemic barriers that affect vaccine uptake in populations that are isolated and underserved by healthcare services need to be monitored and addressed with targeted strategies in order to reduce inequalities in vaccine uptake.
  • In light of the upcoming summer holiday season, travellers should check their vaccination status and consult their general practitioner to ensure they are up-to-date with recommended immunisations prior to departure.


ECDC's latest advice on measles is available in the Threat Assessment Brief 'Measles on the rise in the EU/EEA: Considerations for a public health response', published in February 2024 and the conclusions remain valid. Additional information on the risk classification and ECDC recommendations can be found in this report.

Latest updates for this event

View all